• Genetic TherapyEnrolling

  Study of 4D-710 in Adults with Cystic Fibrosis , protocol number 4DMT 4D-710-C001 (Part 1 and 2)

  This study will test the safety and tolerability of 4D-710, an investigational gene therapy, in adults with CF who are not eligible for or are unable to tolerate CFTR modulator therapy.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50 to 90%

  • Number of Visits:

    22

  • Length of Participation:

    1 years

• Restore CFTR ProteinEnrolling

  Study to evaluate SION-719 in adults with cystic fibrosis who are already taking Trikafta® and have two copies of the F508del mutation. , protocol number Sionna Phase 2a SION-719-201 (PreciSION CF)

  This study will evaluate SION-719 for safety and tolerability, as well as how the body processes it.  The drug is intended to help CFTR function closer to normal, when given to adults with CF who are already taking Trikafta.

  • Age:

    18 Years to 65 Years

  • Mutation(s):

    Two Copies F508del

  • FEV1% Predicted:

    40 to 100%

  • Number of Visits:

    6

  • Length of Participation:

    16 weeks

• Anti-InflammatoryEnrolling

  Study to evaluate BI 1291583 in adults with bronchiectasis , protocol number BI 1397-0014 (Airtivity)

  This study will test the effectiveness, safety, and tolerability of BI 1291583, a drug intended to reduce inflammation in the lungs.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50 to 100%

  • Number of Visits:

    9

  • Length of Participation:

    76 weeks

• Anti-InfectiveEnrolling

  Study to evaluate two antibiotic treatment approaches for the management of outpatient pulmonary exacerbations in children 3 to 18 years old. , protocol number STOP PEDS 2.0 RCT Main Cohort

  The STOP PEDS study will evaluate the safety and effectiveness of two antibiotic treatment approaches for mild pulmonary exacerbations, which are treated at home, in children with CF.

  • Age:

    3 Years to 18 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50% or greater

  • Number of Visits:

    6

  • Length of Participation:

    0 days

• ObservationalEnrolling

  Observational Study to Evaluate Anxiety, Depression, and Behavior Problems in Children With CF (TIDES 2.0) , protocol number TIDES 2.0 (SMITH24A0)

  The researchers conducting this observational study hope to learn more about the prevalence of mental health concerns in children with CF under age 12.

  • Age:

    18 Months to 11 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    3

  • Length of Participation:

    18 months

• OtherEnrolling

  A study to evaluate the insulin-only Bionic Pancreas in people with cystic fibrosis 14 years of age or older who have cystic fibrosis-related diabetes (CFRD) , protocol number Bionic Pancreas CFRD IOBP V 1.0.

  This study will evaluate the effectiveness and safety of using the insulin-only Bionic Pancreas (BP) system compared to using one’s usual insulin delivery method.

  • Age:

    14 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    4

  • Length of Participation:

    7 months

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.